Mob.:
+86 156 3115 5652
Mob.:
+86 156 3115 5652
E-mail:
thinkdo_calvin@126.com/thinkdochem@126.com
Mob.:
+86 156 3115 5652
Mob.:
+86 156 3115 5652
E-mail:
thinkdo_calvin@126.com/thinkdochem@126.com
News
When I choose a liquid potassium polyaspartate concentration, I begin with the target active dosage rather than the product volume. For most wine stabilization trials, I would start near 100 mg/L active potassium polyaspartate, then increase toward 200 mg/L only when wine-instability testing shows that the lower dose is insufficient. The final amount must remain within the legal limit for the destination market and the supplier’s technical instructions.
| Liquid KPA strength* | Active KPA per mL | Volume for 100 mg/L | Volume for 200 mg/L |
|---|---|---|---|
| 5% | 50 mg/mL | 2.0 mL/L | 4.0 mL/L |
| 10% | 100 mg/mL | 1.0 mL/L | 2.0 mL/L |
| 20% | 200 mg/mL | 0.5 mL/L | 1.0 mL/L |
*The table assumes the stated concentration is expressed as active KPA on a weight-per-volume basis. If the product is labeled weight-per-weight, I must also use its density before converting milligrams per liter into milliliters per liter.
!
Liquid potassium polyaspartate is a wine-treatment product based on Potassium Polyaspartic Acid, commonly used to reduce the risk of potassium hydrogen tartrate crystallization. These crystals, often called potassium bitartrate crystals, may form when bottled wine is exposed to lower temperatures or changes in ionic balance. The treatment does not replace basic wine analysis, cold-stability testing, or proper filtration control.
I treat product concentration and application dosage as two separate measurements. Concentration describes how much active KPA is present in the commercial liquid, while dosage describes how much active KPA enters the wine. A 5% product and a 20% product can deliver the same stabilization dose, but they require different addition volumes and create different handling, storage, and mixing requirements.
The most important decision factors are the wine’s measured instability, style, processing temperature, protein condition, filtration plan, and destination-market rules. A product selected only because it has the highest stated concentration may create dosing errors if the cellar lacks accurate metering equipment. For that reason, I prefer a product and dosage combination that can be measured repeatedly within approximately ±5% of the intended addition volume.
For a practical first trial, I would normally test 100 mg/L active KPA as the starting point. If the wine remains unstable after treatment, I would compare that result with 150 mg/L and 200 mg/L, provided the product label and applicable regulations permit those levels. I would not automatically use the maximum dose because excessive treatment can increase cost without solving the actual instability mechanism.
The correct dosage depends on the active concentration stated on the technical data sheet. For a 10% liquid KPA product, 100 mg/L active KPA corresponds to approximately 1.0 mL/L under a weight-per-volume assumption. For a 20% product, the same active dose requires approximately 0.5 mL/L, which may be more difficult to meter accurately in a small winery without a calibrated syringe, laboratory pipette, or low-flow dosing pump.
| Target active dosage | 5% liquid KPA | 10% liquid KPA | 20% liquid KPA |
|---|---|---|---|
| 100 mg/L | 2.0 mL/L | 1.0 mL/L | 0.5 mL/L |
| 150 mg/L | 3.0 mL/L | 1.5 mL/L | 0.75 mL/L |
| 200 mg/L | 4.0 mL/L | 2.0 mL/L | 1.0 mL/L |
These values are calculation examples, not universal treatment instructions. Before cellar-scale addition, I would confirm whether the supplier defines concentration as active polymer, dry solids, potassium polyaspartate equivalent, or another analytical basis. I would also check density, pH, storage temperature, shelf life, lot identification, and compatibility instructions.
Potassium hydrogen tartrate, or KHT, becomes less soluble when wine is chilled, concentrated, or exposed to conditions that favor crystal nucleation. In an untreated wine, microscopic tartrate nuclei can develop into visible crystals on the bottle wall or at the bottom of the container. This is a physical stability problem rather than a microbial spoilage problem.
KPA works by interacting with the growing crystal surfaces and limiting further crystal development. In practical terms, the polymer can interfere with the growth of potassium bitartrate crystals after the wine reaches conditions that would otherwise support precipitation. Its effectiveness depends on the wine matrix, the treatment level, mixing efficiency, and whether the wine is actually unstable because of KHT.
KPA is not a universal tartrate treatment. It should not be expected to correct every calcium-tartrate problem, remove pre-existing heavy crystal deposits, or replace clarification and filtration decisions. When I see a suspected tartrate issue, I first identify whether the instability involves potassium hydrogen tartrate, calcium tartrate, or another precipitate.
I use the following formula when the commercial product concentration is expressed as active KPA by weight per volume:
Required product volume in mL/L = target active dosage in mg/L ÷ active KPA concentration in mg/mL
For example, a 10% product contains approximately 100 mg of active KPA per milliliter under a weight-per-volume interpretation. If I want to apply 150 mg/L, I divide 150 mg/L by 100 mg/mL and obtain 1.5 mL/L. For a 10,000-liter tank, the corresponding volume is 15 liters.
| Wine volume | 100 mg/L using 10% product | 150 mg/L using 10% product | 200 mg/L using 10% product |
|---|---|---|---|
| 100 L | 100 mL | 150 mL | 200 mL |
| 1,000 L | 1.0 L | 1.5 L | 2.0 L |
| 10,000 L | 10 L | 15 L | 20 L |
If the product is labeled 10% by weight rather than volume, I cannot safely use the simple table without checking density. A product with a density of 1.10 kg/L would contain approximately 110 g of active material per liter if the 10% value is weight-per-weight. That changes the volume calculation and should be reflected in the cellar dosing worksheet.
Yes, concentrated liquid KPA can often be diluted for easier metering, but I would only do so when the supplier’s instructions permit it. I would use clean, compatible water, a labeled preparation vessel, and a defined dilution ratio. The diluted solution should be prepared close to use, protected from contamination, and identified with concentration, preparation date, operator, and expiry date.
For example, if a 20% product is difficult to meter at 0.5 mL/L, I could prepare a controlled 1:1 dilution to create a nominal 10% working solution. However, the final concentration may shift if the product density, temperature, or mixing method is not considered. I would never dilute a commercial product simply to reduce cost without confirming that the diluted material remains chemically and microbiologically suitable for wine treatment.
I generally apply liquid KPA after fermentation is complete and after the wine has reached the treatment stage defined by the winery’s process. The wine should be reasonably clear, because excessive solids can make mixing and subsequent filtration less predictable. I would avoid adding KPA immediately before an operation that could remove or redistribute the treatment unless the supplier’s technical documentation specifically supports that sequence.
Before addition, I calculate the total treatment volume, confirm the active dosage, and verify the tank’s working volume rather than relying on its nominal capacity. I then introduce the product into a moving wine stream or a recirculation loop to reduce localized concentration. A practical mixing target is to circulate enough wine to achieve at least one complete tank turnover, followed by a defined holding period based on the product instructions and the winery’s validation work.
The addition line, pump, and measuring vessel should be clean and compatible with the treatment product. For small wineries, I would use a calibrated graduated cylinder or laboratory pipette for bench work and a verified dosing pump for tanks above several hundred liters. Each addition should be recorded with tank number, wine volume, product lot, product concentration, active dosage, calculated volume, actual volume, operator, and date.
I would not select a liquid potassium polyaspartate concentration from the label alone. A bench trial provides a controlled way to compare dosage response, especially when the wine has borderline stability or when the treatment will be used on a new variety, vintage, or processing line.
I collect enough wine from the actual tank to prepare at least four treatment levels and one untreated control. A useful first design is 0, 100, 150, and 200 mg/L active KPA, with each treatment prepared in duplicate when sample volume permits. I use identical bottles, consistent sample volumes, and the same mixing procedure for every treatment.
For a 10% product and 250 mL wine samples, the 100 mg/L treatment requires 25 mg of active KPA. At 100 mg/mL product strength, this equals 0.25 mL of commercial product. The 150 mg/L and 200 mg/L treatments require 0.375 mL and 0.50 mL, respectively.
Because these quantities are small, I prefer to prepare an intermediate dilution rather than measure with an imprecise tool. For example, a documented 1:10 working dilution can make the treatment volumes ten times larger, improving measurement repeatability. I would include the dilution water in the calculation and use the same dilution method across every sample.
I add each treatment to the wine while stirring slowly enough to avoid excessive oxygen pickup. After mixing, I label the samples with active dosage, product strength, preparation time, and operator initials. I then hold the samples under the same temperature and time conditions that represent the expected cellar and distribution environment.
For KHT stability, I compare treated samples with the untreated control using the winery’s established cold-stability method. Depending on the laboratory protocol, this may include refrigeration, controlled chilling, conductivity measurement, visual crystal observation, or a combination of methods. The important requirement is consistency: the same temperature, exposure time, sample volume, filtration status, and measurement endpoint should be applied to every treatment.
If the wine is intended for commercial release, I would also check turbidity, filterability, color, aroma, pH, and relevant analytical parameters before and after treatment. A treatment that prevents crystals but causes an unacceptable filtration load may not be suitable for the production line. I would define acceptance criteria before reviewing the results, such as no visible crystals after the specified cold test and turbidity remaining within the winery’s established bottling range.
White and rosé wines often receive close attention for visible crystal formation because the bottle appearance makes any precipitate easy to see. I would normally test the lower end of the active dosage range first, then increase only if the instability test remains positive. The final decision should also consider whether the wine has already undergone cold stabilization or another tartrate-control process.
Red wine can also develop KHT crystals, although color and phenolic composition may change the visual assessment. I would avoid assuming that red wine needs a higher KPA dosage solely because it contains more phenolics. Instead, I would compare untreated and treated samples using the same analytical endpoint and confirm that the product does not create an undesirable change in color, mouthfeel, or filtration behavior.
Sparkling wine requires additional process discipline because pressure, carbonation, dosage timing, and filtration can affect mixing. I would conduct the trial in a matrix that resembles the final sparkling-wine process rather than evaluating only still-wine samples. If the product is added before carbonation, sterile filtration, or final packaging, the winery should verify that the chosen sequence does not reduce treatment performance or compromise the packaging specification.
I use a simple decision process to avoid treating the wrong problem:
Is the instability confirmed as potassium hydrogen tartrate?
If yes, continue with KPA testing. If the precipitate is calcium tartrate, investigate a different treatment strategy.
Does the untreated wine fail the cold-stability test?
If no, avoid routine KPA addition unless there is a documented process reason. If yes, continue.
Does 100 mg/L active KPA pass the stability test?
If yes, use the lowest validated dose. If no, compare 150 mg/L and 200 mg/L, subject to legal and supplier limits.
Is the wine protein-stable and filtration-ready?
If no, resolve protein or clarification issues before final treatment. If yes, continue.
Can the cellar meter the selected product accurately?
If no, choose a different concentration or prepare a controlled working dilution.
Is the treatment permitted in the destination jurisdiction?
If the legal status is unclear, stop and obtain confirmation from the responsible regulatory or technical authority.
This process links dose selection to actual wine behavior rather than treating the commercial concentration as a performance ranking. A 20% product is not automatically more suitable than a 5% product; it simply delivers more active material in each milliliter.
When I compare liquid potassium polyaspartate vs. CMC, I focus on wine matrix, treatment timing, filtration, and regulatory acceptance. Both materials may be used for tartrate stabilization, but their behavior and handling requirements are not identical. CMC can be sensitive to the wine’s colloidal conditions and may require careful attention to protein stability and filtration sequence.
KPA is often considered when the winery wants a treatment that can be integrated into a post-fermentation stabilization program with a defined active dosage. CMC may be appropriate in processes where the formulation, legal status, and filtration protocol have already been validated. I would not select one solely from a general claim about effectiveness because product composition and wine chemistry can produce different results.
| Evaluation factor | Liquid KPA | CMC |
|---|---|---|
| Main stabilization target | Primarily KHT crystal-growth control | Tartrate stabilization, depending on formulation and wine conditions |
| Dose calculation | Based on active KPA concentration and target mg/L | Based on product-specific CMC dosage instructions |
| Key risk | Treating calcium-tartrate instability as KHT instability | Interaction with protein stability, colloids, and filtration |
| Best validation method | Cold-stability trial with dosage ladder | Wine-specific stability and filtration trial |
| Product handling | Liquid metering or controlled dilution | Formulation-dependent; may require careful dispersion |
| Selection priority | Verified active concentration and legal status | Verified compatibility, legal status, and process sequence |
I also compare the supplier’s certificate of analysis, technical data sheet, batch number, storage conditions, and recommended addition procedure. A lower-cost product can create a higher total cost if it requires additional trials, causes filter blockage, or produces inconsistent results between lots. The decision should therefore include treatment cost per treated liter, labor, rejected product risk, filtration cost, and rework exposure.
Metatartaric acid is another treatment associated with tartrate stabilization, but its stability over time and treatment behavior differ from KPA. I would evaluate the expected shelf life, storage conditions, wine pH, treatment timing, and market requirements before choosing between them. Metatartaric acid may be affected by hydrolysis over time, so the expected protection period should be part of the comparison.
KPA may be preferred when the winery’s validation data show consistent KHT crystal-growth control under the intended bottling and distribution conditions. That conclusion must come from testing rather than from assuming that one treatment is universally superior. If the commercial objective involves long-distance shipping, extended shelf storage, or multiple temperature cycles, I would include those conditions in the stability study.
Neither KPA nor metatartaric acid should be used as a substitute for diagnosing calcium-tartrate instability. Calcium tartrate can require separate control measures, and the treatment decision may depend on calcium concentration, tartaric acid balance, pH, and the wine’s processing history. The first question is always whether the observed precipitate matches the mechanism the treatment is designed to address.
Protein stability can affect the suitability of a KPA treatment, especially in white and rosé wines. I would complete the winery’s normal protein-stability assessment before finalizing the KPA dose because unstable proteins may create haze that is unrelated to tartrate precipitation. Treating tartrate instability without controlling protein instability can lead to a false conclusion about the overall treatment result.
Filtration performance also requires measurement. During a bench trial, I would compare turbidity before and after treatment and record filter throughput, differential pressure, and any visible deposit formation. If the treated wine requires a lower filtration rate or reaches the pressure limit earlier, that operational effect should be included in the treatment decision.
For quality compliance, I would retain the product label, technical data sheet, certificate of analysis, safety documentation, lot number, dosage calculation, bench-trial results, and final addition record. I would also verify that the product is approved or permitted for the intended use in each sales jurisdiction. Regulatory limits and labeling requirements can differ by market, so a technical decision made for one country may not transfer directly to another.
When I evaluate a supplier such as Think-Do Chemicals, I separate the product’s technical suitability from the supplier’s operational reliability. I request a current technical data sheet, certificate of analysis, specification limits, batch-release information, packaging details, storage requirements, and a documented shelf-life period. I also ask whether the quoted concentration refers to active KPA, total solids, or another basis.
For delivery planning, I would record the minimum order quantity, standard lead time, production capacity reserved for repeat orders, export documentation, packaging format, and available logistics options. A winery that uses 10 liters per tank but purchases in 200-liter drums should calculate the risk of partial-container storage and product aging. The purchasing decision should include at least one approved backup lot or alternative supplier if a bottling schedule depends on the treatment.
I also look for measurable batch controls, such as concentration range, pH range, density range, appearance, viscosity, and microbiological specifications where applicable. If these values are not listed, I would ask the supplier to provide them before approving the product. For commercial use, a retained sample from each lot can support investigation if wine stability changes after treatment.
The purchase price per kilogram or liter does not show the full treatment cost. I calculate the cost per treated liter using the formula:
Treatment cost per liter = product price per liter × product volume required per liter of wine
For a 10% product applied at 1.0 mL/L, one liter of commercial product treats approximately 1,000 liters of wine at a 100 mg/L active dosage. At 2.0 mL/L, the same liter treats approximately 500 liters. This conversion allows me to compare products with different concentrations on an active-dose basis instead of comparing container prices.
| Product strength | Product volume at 100 mg/L | Approximate wine treated per 1 L product |
|---|---|---|
| 5% | 2.0 mL/L | 500 L |
| 10% | 1.0 mL/L | 1,000 L |
| 20% | 0.5 mL/L | 2,000 L |
I also include labor, dosing equipment calibration, tank mixing time, bench trials, filtration impact, storage losses, and disposal of expired material. If a higher-concentration product requires specialized low-volume equipment that costs $1,000 to install and maintain, its lower addition volume may not reduce total cost for a small winery. Conversely, a 5% product may be easier to meter accurately but require more storage space and more frequent replenishment.
The economic benefit should be measured against a defined failure cost. That cost may include returned bottles, rework, relabeling, additional cold storage, customer complaints, or delayed release. I would compare the treatment cost with the avoided cost of confirmed crystal-related failures, using actual winery records instead of an unverified return-on-investment claim.
The first common mistake is confusing commercial liquid concentration with active dosage. A 20% product does not mean the wine receives 20% KPA; it means the product contains approximately 200 mg active material per milliliter under the stated concentration basis. Every cellar worksheet should show both the target active dosage in mg/L and the required product volume in mL/L.
The second mistake is using the product density incorrectly or ignoring whether the label uses weight-per-weight or weight-per-volume. This can create a material dosing error, especially with concentrated products. I would confirm the calculation with the supplier’s technical team before applying the product to a large tank.
The third mistake is treating an unconfirmed precipitate. KPA is aimed primarily at KHT-related instability, so it may not solve calcium-tartrate precipitation. If the wine fails for another reason, increasing KPA from 100 mg/L to 200 mg/L can increase cost without correcting the cause.
The fourth mistake is skipping the bench trial. A dosage that works for one vintage may not produce the same result in another wine with different pH, potassium, calcium, alcohol, colloid, and phenolic conditions. I prefer to test at least three active dosage levels and retain an untreated control before approving the cellar addition.
What Concentration of Liquid Potassium Polyaspartate Should You Choose? I recommend choosing the product strength that allows accurate measurement while delivering a validated active dosage, rather than choosing the most concentrated liquid by default. Start near 100 mg/L active KPA, test 150 mg/L and 200 mg/L only when instability remains, and never exceed the applicable legal limit or supplier instruction.
For a 5% product, the starting calculation is approximately 2.0 mL/L; for a 10% product, 1.0 mL/L; and for a 20% product, 0.5 mL/L. I would verify the concentration basis, density, and dosage instructions against the current technical data before preparing any tank addition. The final selection should be supported by a cold-stability trial, protein-stability review, filtration assessment, and documented batch-control process.
For small wineries, a 10% product may provide a practical balance between measurable addition volume and storage efficiency. For larger commercial operations with calibrated dosing equipment, a 20% product may reduce handling volume, while a 5% product may simplify low-volume bench work. In every case, the best decision combines wine chemistry, testing results, legal compliance, delivery planning, and total cost per treated liter.
